

DAFTAR PUSTAKA

- Ahn, J.H., Hyun, J.Y., Jeong, M.H., Kim, J.H., Hong, Y.J., Sim, D.S., Kim, M.C., Park, H.S., Kim, D.I., Hur, S.H., Oh, S.K., Ahn, Y. 2021. Comparative Effect Of Angiotensin Converting Enzyme Inhibitor Versus Angiotensin II Type I Receptor Blocker In Acute Myocardial Infarction With Non-Obstructive Coronary Arteries; From The Korea Acute Myocardial Infarction Registry - National Institute of Health. *Cardiology journal*, 28(5), pp. 738–745. doi:10.5603/CJ.a2020.0130.
- Ann, S.H., Strauss, M.H., Park, G.M., Han, S., Yang, Y., Kim, Y.G., Won, K.B., Kim, S.J., Lee, S.G., Cho, Y.R., Kim, D.W., Park, M.W., Her, S.H., Lee, S.W. 2020. Comparison Between Angiotensin-Converting Enzyme Inhibitor And Angiotensin Receptor Blocker After Percutaneous Coronary Intervention. *International Journal of Cardiology*, 306, pp. 35–41. doi:https://doi.org/10.1016/j.ijcard.2019.11.086.
- Atlas, S. 2007. *The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition*. Available at: www.amcp.org.
- Barreras, A. dan Gurk-Turner, C. 2003. *Pharmacology Notes Angiotensin II Receptor Blockers*. BUMC PROCEEDINGS.
- Budreviciute, A., Damiati, S., Sabir, D.K., Onder, K., Goetzburg, P.S., Plakys, G., Katileviciute, A., Khoja, S., Kodzius, R. 2020. Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors. *Frontiers in Public Health*. Frontiers Media S.A. doi:10.3389/fpubh.2020.574111.
- Choi, I.S., Park, I.B., Lee, K., Ahn, T.H., Kim, J.H., Ahn, Y., Chae, S.C., Kim, H.S., Kim, Y.J., Cho, M.C., Kim, C.J., Jeong, M.H., Lee, D.H. 2018. Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge. *Journal of Cardiovascular Pharmacology and Therapeutics*, 24(2), pp. 120–129. doi:10.1177/1074248418795897
- Dickstein, K. dan Kjekshus, J. 2002. Effects Of Losartan And Captopril On Mortality And Morbidity In High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial, Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. *Lancet*

- (London, England), 360(9335), pp. 752–760. doi:10.1016/S0140-6736(02)09895-1.
- Duchene, J. dan Bader, M. 2010. Bradykinin B2 Receptor Agonism: A Novel Therapeutic Strategy for Myocardial Infarction?. *American Journal of Hypertension*, 23(5), pp. 459–459. doi:10.1038/AJH.2010.32.
- Ennezat, P.V., Berlowitz, M., Sonnenblick, E.H., Le Jemtel, T.H. 2000. Therapeutic Implications Of Escape From Angiotensin-Converting Enzyme Inhibition In Patients With Chronic Heart Failure. *Current cardiology reports*, 2(3), pp. 258–262. doi:10.1007/S11886-000-0077-3.
- Farissa, I.P. 2012. Komplikasi Pada Pasien Infark Miokard Akut ST-Elevasi (STEMI) Yang Mendapat Maupun Tidak Mendapat Terapi Reperfusi.
- Farsang, C. 2011. Indications For And Utilization Of Angiotensin Receptor II Blockers In Patients At High Cardiovascular Risk. *Vascular Health and Risk Management*. DOVE Medical Press Ltd., pp. 605–622. doi:10.2147/VHRM.S23468.
- Fountain, J.H. dan Lappin, S.L. 2021. Physiology, Renin Angiotensin System. StatPearls [Preprint]. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK470410> (Accessed: October 2, 2021).
- Goyal, A., Cusick, A.S. dan Thielemier, B. 2021. ACE Inhibitors. StatPearls [Preprint]. Available at: <https://pubmed.ncbi.nlm.nih.gov/28613646/> (Accessed: October 2, 2021).
- Hara, M., Sakata, Y. dan Nakatani, D. 2014. Comparison of 5-Year Survival After Acute Myocardial Infarction Using Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker. *The American Journal of Cardiology* [Preprint]. doi:10.1016/j.amjcard.2014.03.055.
- Her, A.Y., Choi, B.G., Rha, S.W., Kim, Y.H., Choi, C.U., Jeong, M.H. 2020. The Impact Of Angiotensin-Converting-Enzyme Inhibitors Versus Angiotensin Receptor Blockers On 3-Year Clinical Outcomes In Patients With Acute Myocardial Infarction Without Hypertension. *PloS one*, 15(11), p. e0242314. doi:http://dx.doi.org/10.1371/journal.pone.0242314.
- Herman, L.L., Padala, S.A., Ahmed, I., Bashir, K. 2021. Angiotensin Converting Enzyme Inhibitors. StatPearls. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28613705> (Accessed: October 2, 2021).

- Hill, R.D. dan Vaidya, P.N. 2021. Angiotensin II Receptor Blockers. StatPearls [Preprint]. Available at: <https://pubmed.ncbi.nlm.nih.gov/30725712/> (Accessed: October 2, 2021).
- Joanna Briggs Institute. 2020. Available at: <https://jbi.global/critical-appraisal-tools> (Accessed: October 2, 2021).
- Kementerian Kesehatan. 2018. Riset Kesehatan Dasar 2018.
- Kim, G.S., Ko, Y.G., Suh, Y., Won, H., Hong, S.J., Ahn, C.M., Kim, J.S., Kim, B.K., Choi, D., Hong, M.K., Jang, Y. 2020. Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014). *Korean circulation journal*, 50(11), pp. 984–994. doi:10.4070/kcj.2020.0057.
- Kozma, C.M., Dickson, M., Phillips, A.L., Meletiche, D.M. 2013. Medication Possession Ratio: Implications Of Using Fixed And Variable Observation Periods In Assessing Adherence With Disease-Modifying Drugs In Patients With Multiple Sclerosis. *Patient preference and adherence*, 7, p. 509. doi:10.2147/PPA.S40736.
- Lang, C.C. dan Struthers, A.D. 2013. Targeting The Renin-Angiotensin-Aldosterone System In Heart Failure. *Nature reviews. Cardiology*, 10(3), pp. 125–134. doi:10.1038/NRCARDIO.2012.196.
- Lee, J.H., Bae, M.H., Yang, D.H., Park, H.S., Cho, Y., Lee, W.K., Jeong, M.H., Kim, Y.J., Cho, M.C., Kim, C.J., Chae, S.C. 2016. Angiotensin II Type 1 Receptor Blockers As A First Choice In Patients With Acute Myocardial Infarction. *The Korean journal of internal medicine*, 31(2), pp. 267–276. doi:10.3904/kjim.2014.268.
- Lim, S., Choo, E.H., Choi, I.J., Ihm, S.H., Kim, H.Y., Ahn, Y., Chang, K., Jeong, M.H., Seung, K.B. 2019. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. *Journal of Korean medical science*, 34(45), p. e289. doi:10.3346/jkms.2019.34.e289.
- McMurray, J.J.V. 2008. ACE Inhibitors In Cardiovascular Disease-Unbeatable?. *The New England journal of medicine*, 358(15), pp. 1615–1616. doi:10.1056/NEJME0801925.

- Mechanic, Oren J, Gavin, M. dan Grossman, S.A. 2021. Acute Myocardial Infarction. StatPearls [Preprint]. Available at: <https://pubmed.ncbi.nlm.nih.gov/29083808/> (Accessed: October 2, 2021).
- Morimoto, T., Gandhi, T.K., Fiskio, J.M., Seger, A.C., So, J.W., Cook, E.F., Fukui, T., Bates, D.W. 2004. An Evaluation Of Risk Factors For Adverse Drug Events Associated With Angiotensin-Converting Enzyme Inhibitors. *Journal of evaluation in clinical practice*, 10(4), pp. 499–509. doi:10.1111/J.1365-2753.2003.00484.X.
- Ojha, N. dan Dhamoon, A.S. 2021. Myocardial Infarction. StatPearls [Preprint]. Available at: <https://pubmed.ncbi.nlm.nih.gov/30725761/> (Accessed: October 2, 2021).
- Patel, S., Rauf, A., Khan, H., Abu-Izneid, T. 2017. Renin-Angiotensin-Aldosterone (RAAS): The Ubiquitous System For Homeostasis And Pathologies. *Biomedicine & Pharmacotherapy*, 94, pp. 317–325. doi:10.1016/J.BIOPHA.2017.07.091.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2015. Pedoman Tatalaksana Sindrom Koroner Akut Edisi Ketiga.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2019. Pedoman Evaluasi Dan Tatalaksana Angina Pectoris Stabil.
- Pfeffer, M.A., McMurray, J.J.V., Velazquez, E.J., Rouleau, J., Kober, L., Maggioni, A.P., Solomon, S.D., Swedberg, K., Van de Werf, F., White, H., Leimberger, J.D., Henis, M., Edwards, S., Zelenkofske, S., Sellers, M.A., and Califf, R.M. 2003. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *The New England journal of medicine*, 349(20), pp. 1893–1906. doi:10.1056/NEJMOA032292.
- PRISMA. 2021. Available at: <http://www.prisma-statement.org/> (Accessed: October 2, 2021).
- Reilly, R., Evans, K., Gomersall, J., Gorham, G., Peters, M.D.J., Warren, S., O’Shea, R., Cass, A., and Brown, A. 2016. Effectiveness, Cost Effectiveness, Acceptability And Implementation Barriers/Enablers Of Chronic Kidney Disease Management Programs For Indigenous People In Australia, New Zealand And Canada: A Systematic Review Of Mixed Evidence. *BMC Health Services Research*, 16(1). doi:10.1186/s12913-016-1363-0.

- Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., Anderson, C. 2008. Telmisartan, Ramipril, Or Both In Patients At High Risk For Vascular Events. *The New England journal of medicine*, 358(15), pp. 1547–1559. doi:10.1056/NEJMOA0801317.
- Saleh, M. dan Ambrose, J.A. 2018. *Understanding Myocardial Infarction*. F1000Research. F1000 Research Ltd. doi:10.12688/f1000research.15096.1.
- Shahjehan, R.D. dan Bhutta, B.S. 2021. Coronary Artery Disease. *3D Echocardiography*, pp. 27–35. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK564304/> (Accessed: October 19, 2021).
- Siswanto. 2010. *Systematic Review Sebagai Metode Penelitian Untuk Mensintesis Hasil-Hasil Penelitian (Sebuah Pengantar)*. *Buletin Penelitian Sistem Kesehatan*, 13(4).
- Strauss, M.H. dan Hall, A.S. 2006. Angiotensin Receptor Blockers May Increase Risk Of Myocardial Infarction Unraveling The ARB-MI Paradox. *Circulation*, 114(8), pp. 838–854. doi:10.1161/CIRCULATIONAHA.105.594986.
- Thygesen, K., Alpert, J.S., Jaffe, A.S., Chaitman, B.R., Bax, J.J., Morrow, J.J., White, H.D., Mickley, H., Crea, F., Van De Werf, F., Bucciarelli-Ducci, C., Katus, H.A., Pinto, F.J., Antman, E.M., Hamm, C.W., De Caterina, R., Januzzi, J.L., Apple, F.S., Garcia, M.A.A., Richard, U.S., Canty, J.M., Lyon, A.R., Devereaux, P.J., Zamorano, J.L., Lindahl, B., Weintraub, W.S., Kristin, N.L., Virmani, R., Vranckx, P., Cutlip, D., Gibbons, R.J., Smith, S.C., Atar, D., Luepker, R.V., Robertson, R.M., Bonow, R.O., Gabriel, S.P., O’Gara, P.T., A Fox, K.A. 2018. Fourth Universal Definition Of Myocardial Infarction. *Kardiologia Polska*, 76(10), pp. 1383–1415. doi:10.5603/KP.2018.0203.
- Usman, Y., Iriawan, R.W., Rosita, T., Lusiana, M., Kosen, S., Kelly, M., Forsyth, S., Rao, C. 2018. Indonesia’s Sample Registration System In 2018: A Work In Progress. *Journal of Population and Social Studies*, 27(1), pp. 39–52. doi:10.25133/JPSSV27N1.003.
- World Health Organization. 2021. Noncommunicable diseases: Mortality. Available at: <https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-mortality> (Accessed: October 2, 2021).

Yunanto Setyaji, D., Suryo Prabandari, Y. dan Made Alit Gunawan, I. 2018. Aktivitas fisik dengan penyakit jantung koroner di Indonesia. *Jurnal Gizi Klinik Indonesia*, 14. Available at: <https://jurnal.ugm.ac.id/jgki>.